AUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE YEAR ENDED 31-03-2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Samsrita Labs Limited (formerly Dr Habeebullah Life Sciences) reported audited results for FY25 and Q4 FY25. The company showed no revenue from operations and no other income reported. Total expenses stood at Rs 25.95 lakhs for FY25 (vs Rs 24.99 lakhs in FY24), resulting in a loss before and after tax of Rs 25.95 lakhs (FY24: Rs 24.99 lakhs loss). Loss per share for the year widened slightly to Rs (0.18) from Rs (0.17). Operating cash flow remained negative at Rs (22.53) lakhs, deteriorating from Rs (12.88) lakhs in FY24, funded mainly through borrowings which rose to Rs 242.68 lakhs (from Rs 220.32 lakhs). Accumulated reserves are deeply negative at Rs (272.50) lakhs. The board also appointed M/s Tungala & Co. as internal auditors and Manoj Parakh & Associates as secretarial auditors. The statutory auditors (MGR & Co.) issued an unmodified audit opinion.
The company appears effectively non-operational with nil revenue, widening losses, negative operating cash flows, and eroded reserves. For shareholders, this signals a dormant or pre-revenue company whose survival depends on continued borrowings; the stock price may remain illiquid and volatile without operational turnaround.